Aredia: the once-monthly infusion for the treatment of bone metastases.

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Cancer cells produce a variety of cytokines that stimulate osteoclasts to resorb bone, leading to cancer-mediated destruction of the skeleton. Bisphosphonates, which are deposited on the surface of bone as a response to increased resorption, are potent inhibitors of this osleoclastic resorption. Several studies have suggested that bisphosphonate therapy can retard the formation of new bone metastases in patients with metastatic bone disease. First-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment and have now been superseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adverse effects on bone mineralization. Further generations of these drugs have now entered clinical trials.

Original languageEnglish (US)
JournalCurrent Opinion in Oncology
Volume10 Suppl 1
StatePublished - Aug 1998

Fingerprint

pamidronate
Diphosphonates
Neoplasm Metastasis
Bone and Bones
Etidronic Acid
Clodronic Acid
Physiologic Calcification
Bone Diseases
Osteoclasts
Therapeutics
Osteogenesis
Skeleton
Neoplasms
Clinical Trials
Cytokines
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

@article{f92c0197fac84eb39d30972bfdf5f325,
title = "Aredia: the once-monthly infusion for the treatment of bone metastases.",
abstract = "Cancer cells produce a variety of cytokines that stimulate osteoclasts to resorb bone, leading to cancer-mediated destruction of the skeleton. Bisphosphonates, which are deposited on the surface of bone as a response to increased resorption, are potent inhibitors of this osleoclastic resorption. Several studies have suggested that bisphosphonate therapy can retard the formation of new bone metastases in patients with metastatic bone disease. First-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment and have now been superseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adverse effects on bone mineralization. Further generations of these drugs have now entered clinical trials.",
author = "Allan Lipton",
year = "1998",
month = "8",
language = "English (US)",
volume = "10 Suppl 1",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",

}

Aredia : the once-monthly infusion for the treatment of bone metastases. / Lipton, Allan.

In: Current Opinion in Oncology, Vol. 10 Suppl 1, 08.1998.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aredia

T2 - the once-monthly infusion for the treatment of bone metastases.

AU - Lipton, Allan

PY - 1998/8

Y1 - 1998/8

N2 - Cancer cells produce a variety of cytokines that stimulate osteoclasts to resorb bone, leading to cancer-mediated destruction of the skeleton. Bisphosphonates, which are deposited on the surface of bone as a response to increased resorption, are potent inhibitors of this osleoclastic resorption. Several studies have suggested that bisphosphonate therapy can retard the formation of new bone metastases in patients with metastatic bone disease. First-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment and have now been superseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adverse effects on bone mineralization. Further generations of these drugs have now entered clinical trials.

AB - Cancer cells produce a variety of cytokines that stimulate osteoclasts to resorb bone, leading to cancer-mediated destruction of the skeleton. Bisphosphonates, which are deposited on the surface of bone as a response to increased resorption, are potent inhibitors of this osleoclastic resorption. Several studies have suggested that bisphosphonate therapy can retard the formation of new bone metastases in patients with metastatic bone disease. First-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment and have now been superseded by second-generation bisphosphonates (pamidronate), which are more potent and do not have adverse effects on bone mineralization. Further generations of these drugs have now entered clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0032129993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032129993&partnerID=8YFLogxK

M3 - Review article

C2 - 9801852

AN - SCOPUS:0032129993

VL - 10 Suppl 1

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

ER -